Health and Healthcare

Animal Health Firm IPO Soars (ZTS)

Cattle
Thinkstock
Zoetis Inc. (NYSE: ZTS), a spin-off of the animal health business of Pfizer Inc. (NYSE: PFE), held its initial public offering this morning. The company offered 86.1 million shares at $26 a share, $1.00 above the estimated range of $22 to $25. Pfizer will retain about 83% of the company’s stock, which would shrink to about 80% if underwriters exercise their overallotment options in full.

Zoetis will receive none of the $2.2 billion proceeds from the offering, all of which will go to a debt-for-equity exchanges with some underwriters to pay down Pfizer debt. Pfizer has also indicated that following the IPO it may distribute all or part of its stake in Zoetis to Pfizer shareholders in a tax-free distribution either as a one-time dividend or a share exchange, or possibly both.

The new company expects annual sales of around $4.2 billion and is the largest firm in the animal health industry. Some two-thirds of its sales come from products and services for livestock. The company has operations in 60 companies and competes with in-house animal health units of several big drugmakers, including Sanofi (NYSE: SNY), Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK).

Shares of Zoetis are up nearly 19%, at $30.85 after hitting a high of $31.50 on the first morning of trading. Pfizer’s shares are up about 1.5% at $27.68, near the top of the stock’s 52-week range of $20.75 to $28.84.

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.